Lenvanix

First new frontline treatment option for HCC approved in Japan, Lenvatinib is amultikinase inhibitor that interrupts the pathways of VEGFR1,VEGFR2 and VEGFR3. It is used in the treatment of differentiated thyroid cancer (DTC), renal Cell Carcinoma and Hepatocellular Carcinoma (HCC).

Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet-derived growth factor receptor alpha (PDGFR ), KIT, and RET. Lenvatinib also exhibited antiproliferative activity in hepatocellular carcinoma cell lines dependent on activated FGFR signaling with concurrent inhibition of FGF-receptor substrate 2 (FRS2 ) phosphorylation.

Features